Melatonin and its physiological and therapeutic properties

被引:60
|
作者
Nowak, JZ
Zawilska, JB
机构
[1] Polish Acad Sci, Inst Biogen Amines, PL-90950 Lodz, Poland
[2] Med Univ Lodz, Dept Pharmacodynam, Lodz, Poland
来源
PHARMACY WORLD & SCIENCE | 1998年 / 20卷 / 01期
关键词
melatonin; pineal gland; serotonin N-acetyltransferase; circadian rhythm; seasonal reproduction; circadian rhythm sleep disorders; free radicals;
D O I
10.1023/A:1008688724058
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Melatonin is a hormone produced mainly by the pineal gland in most vertebrate species, including humans. Recent metabolic, receptor and functional studies created a picture of the melatoninergic system(s) in living organisms, its organization, physiology and a role in some pathologic conditions. The melatonin-generating system is characterized by three basic features: (1) photosensitivity (2) diurnal (or circadian) rhythmicity (with highest levels of melatonin production occurring at night in darkness), and oc (3) age-related decline in its activity. Cyclic nocturnal increases of melatonin levels are proportional to the length of nights (or dark periods of an imposed light-dark cycle); the hormone thus conveys a photoperiodic message, and functions in an organism as an internal biochemical clock and calendar. Biological actions OF melatonin are mediated via specific melatonin receptors, whose distribution in the body is uneven, yet with decisively highest density in the suprachiasmatic nuclei of the hypothalamus, pars tuberalis of the pituitary, and the retina (particularly in birds and lower vertebrates) Such a distribution of melatonin receptors suggests that the principal physiological role of the hormone is related to both chronobiology and modulating of the body hormonal milieu. This review surveys recent developments in the melatonin field, and summarizes current knowledge on the melatoninergic mechanisms, including the therapeutic aspect related to the hormone.
引用
收藏
页码:18 / 27
页数:10
相关论文
共 50 条
  • [21] Therapeutic potential of melatonin and its derivatives in aging and neurodegenerative diseases
    Avnish Kumar Verma
    Sandeep Singh
    Syed Ibrahim Rizvi
    Biogerontology, 2023, 24 : 183 - 206
  • [22] PHYSIOLOGICAL AND PHARMACOLOGICAL PROPERTIES OF ADENOSINE - THERAPEUTIC IMPLICATIONS
    DAVAL, JL
    NEHLIG, A
    NICOLAS, F
    LIFE SCIENCES, 1991, 49 (20) : 1435 - 1453
  • [23] ADENINE COMPOUNDS, THEIR CHEMICAL, PHYSIOLOGICAL, AND THERAPEUTIC PROPERTIES
    STEWART, ED
    JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION-SCIENTIFIC EDITION, 1949, 38 (01): : 3 - 9
  • [24] PHYSIOLOGICAL EFFECT OF 5-METHOXYTRYPTAMINE IS NOT DUE TO ITS CONVERSION TO MELATONIN
    RAYNAUD, F
    MIGUEL, JL
    VIVIENROELS, B
    MASSONPEVET, M
    PEVET, P
    ARCHIVES INTERNATIONALES DE PHYSIOLOGIE DE BIOCHIMIE ET DE BIOPHYSIQUE, 1988, 96 (04): : A467 - A467
  • [25] Melatonin as an antioxidant: An assessment of its properties in vitro
    Tang, PL
    Chan, TY
    Qian, ZM
    MELATONIN: A UNIVERSAL PHOTOPERIODIC SIGNAL WITH DIVERSE ACTIONS, 1996, 21 : 167 - 173
  • [26] CURARE - A REVIEW OF ITS THERAPEUTIC EFFECTS AND THEIR PHYSIOLOGICAL BASIS
    SCHLESINGER, EB
    AMERICAN JOURNAL OF MEDICINE, 1946, 1 (05): : 518 - 530
  • [27] Melatonin and its bioisosteres as potential therapeutic agents for the treatment of retinopathy of prematurity
    Osipova, N. A.
    Panova, A. Y.
    Efremov, A. M.
    Lozinskaya, N. A.
    Beznos, O. V.
    Katargina, L. A.
    CHEMICAL BIOLOGY & DRUG DESIGN, 2024, 103 (03)
  • [28] Therapeutic potential of melatonin related to its role as an autophagy regulator: A review
    Boga, Jose A.
    Caballero, Beatriz
    Potes, Yaiza
    Perez-Martinez, Zulema
    Reiter, Russel J.
    Vega-Naredo, Ignacio
    Coto-Montes, Ana
    JOURNAL OF PINEAL RESEARCH, 2019, 66 (01)
  • [29] EFFECT OF MELATONIN UPON HUMAN BRAIN - ITS POSSIBLE THERAPEUTIC IMPLICATIONS
    ANTONTAY, F
    DIAZ, JL
    FERNANDE.A
    LIFE SCIENCE PART 1 PHYSIOLOGY & PHARMACOLOGY, 1971, 10 (15): : 841 - &
  • [30] Therapeutic applications of melatonin
    Kostoglou-Athanassiou, Ifigenia
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2013, 4 (01) : 13 - 24